We are pleased with our performance in 2005. The year was highlighted by the filing of the new drug application on NRP104, our lead compound under development, for the treatment of Attention Deficit Hyperactivity Disorder in pediatric populations. We believe that this advancement together with the progress on our other pipeline products positions us well for future growth. Looking forward, we anticipate receiving approval from the FDA on NRP104 in the second half of 2006 and making IND filings on NRP409 and NRP388, the two most advanced candidates in our preclinical pipeline, by the end of the second quarter of 2006. In addition, we plan to continue to develop NRP290, our second most advanced compound, and other drug products in our research pipeline.
Quotes about preclinical (4 Quotes)
It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.
Taking a long-term view, we fully expect China's eventual emergence as a full-fledged RD hub in any global network. Capabilities in chemistry and clinical research are already well established with great potential for rapid growth in biology and preclinical development.
It's our technology, with their knowledge of the preclinical side and our ability to ultimately go through the regulatory process and manufacture large quantities of vaccine that would make this marriage work.